90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. - Janik JE; Morris JC; O'Mahony D; Pittaluga S; Jaffe ES; Redon CE; Bonner WM; Brechbiel MW; Paik CH; Whatley M; Chen C; Lee JH; et al. (Proceedings of the National Academy of Sciences of the United States of America, 2015)